raloxifene
Sign in to saveRaloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. For osteoporosis it is less preferred than bisphosphonates. It is also used to reduce the risk of breast cancer in those at high risk. It is taken by mouth.
Article
22 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Overdose
- Pharmacology
- Pharmacodynamics
- Mechanism of action
- Clinical effects
- Pharmacokinetics
- Absorption
- Distribution
- Metabolism
- Elimination
- Chemistry
- History
- Society and culture
- Names
- Availability
- Controversy
- Research
- References
- Further reading
Raloxifene, sold under the brand name Evista among others, is a medication used to prevent and treat osteoporosis in postmenopausal women and those on glucocorticoids. For osteoporosis it is less preferred than bisphosphonates. It is also used to reduce the risk of breast cancer in those at high risk. It is taken by mouth.
Common side effects include hot flashes, leg cramps, swelling, and joint pain. Severe side effects may include blood clots and stroke. Use during pregnancy may harm the baby. The medication may worsen menstrual symptoms. Raloxifene is a selective estrogen receptor modulator (SERM) and therefore a mixed agonist–antagonist of the estrogen receptor (ER). It has estrogenic effects in bone and antiestrogenic effects in the breasts and uterus.
Gallery (2)
Connections
Categories
1-Piperidinyl compounds4-Hydroxyphenyl compoundsBenzothiophenesChemical articles with multiple CAS registry numbersChemicals using indexlabelsCYP2B6 inhibitorsDiarylketonesDrugs developed by Eli Lilly and CompanyDrugs with non-standard legal statusECHA InfoCard ID from WikidataEthanolaminesGPER agonists